INTRODUCTION
Krukenberg tumor is named after Friedrich Ernst Krukenberg who described five cases of Krukenberg tumors in 1896 while working as a student in a laboratory in Germany. 1 Krukenberg tumor accounts for only 2% of ovarian cancers. 1 Histologically, it is characterized by Signet ring cells. 1 The lesions are usually not discovered until primary disease is advanced and therefore most patients die within a year. The presence of ovarian metastasis in gastrointestinal malignancy worsens the prognosis.
The present case highlights the possibility of missing the diagnosis of a metastatic disease and subjecting the patient to a surgery and also the dilemma of a surgeon in deciding the treatment for such a disease. The current standard treatment for patients with metastatic gastric cancer is systemic chemotherapy. Recently, many studies have shown that primary debulking surgery improves overall survival.
CASE REPORT
A 43year old P4L4 with regular cycles had complaints of abdominal distension, dysuria and pain during defecation. She was evaluated at another hospital and was diagnosed to have a right ovarian complex mass for which she underwent Laparoscopic right ovariotomy. Her CA-125 was 9.23. Intra-op there was no extra-ovarian disease. Opposite ovary was normal. Histopathology report-Sex cord stromal tumor-unclassified. Few Signet-ring cells were seen. The prognosis related to timing of definitive diagnosis of Krukenberg tumor; whether before, after or at the same time as diagnosis of primary tumor, the role of prophylactic oophorectomy in patients with gastrointestinal malignancies and role of primary debulking and definitive treatment modality are still debated. In the past, a stage 4 disease like Krukenberg tumor was treated with systemic chemotherapy alone. Then came the role of palliative surgical resection of ovarian mass to relieve the pressure symptoms. Many surgeons consider that the current standard treatment for patients with metastatic gastric cancer is systemic chemotherapy. Recently, many studies are going on to know whether a complete cytoreductive surgery which includes removal of the primary as well as the secondary tumor can improve quality of life and survival rate. For Krukenberg tumors, it is not known whether metastasectomy is associated with additional benefits. [2] [3] [4] [5] [6] [7] Bakalakos et al have reported that, in patients with metastatic carcinomas, aggressive surgical therapy may be less beneficial. 8 Meanwhile, several other studies have observed the significance of resection of ovarian metastasis. Jiang et al and Cheong et al reported that ovarian metastasectomy significantly lengthens overall survival in patients with primary gastric, colorectal or breast cancer. 6, 7 A study conducted by Li-Chun Lu et al 2 and Fujiwara et al also concluded that metastasectomy benefits the patient. 8 Dora, Wing, Moon et al are of the opinion that although recurrence after resection of Krukenberg tumor is common, bilateral salpingoovariotomy should be considered and a more aggressive approach such as debulking surgery is recommended to improve the outcome of the patients. 9 Now, cytoreductive surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) has become a potentially curative treatment for intra-abdominal metastasis from colorectal malignancies. 10 In patients with gastrointestinal malignancy, some surgeons even recommend prophylactic oophorectomy during cytoreduction for peritoneal carcinomatosis owing to high risk of ovarian metastasis. Controversies still exist about treatment of Krukenberg tumor. More prospective studies are needed to reach a common conclusion on treatment modality. Due to lack of proper studies, these patients should not be denied the optimum treatment for their disease.
